Skip to main
RCEL

RCEL Stock Forecast & Price Target

RCEL Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

AVITA Medical reported full-year 2025 revenue of approximately $71.6 million, representing an 11% increase from $64.3 million in 2024 and aligning with the company’s revised guidance. The company also improved its net cash use sequentially to approximately $5.1 million, down from $6.2 million in the third quarter, indicating enhanced financial efficiency. Looking ahead, management has provided a 2026 revenue guidance of $80 million to $85 million, suggesting renewed commercial momentum through deeper penetration in burn and trauma centers as well as a broadened product portfolio.

Bears say

AVITA Medical's financial outlook has weakened, leading to a downward revision of revenue expectations and a target valuation decrease from $14.0 to $10.0. The company's net loss remained unchanged at $11.6 million for the latest period, reflecting a loss per share of $0.38, slightly improving from the prior year's loss of $0.44 per share. Given the reliance on a single product, the RECELL system, and a limited international marketing strategy, concerns about sustainable growth persist.

RCEL has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AVITA Medical Inc (RCEL) Forecast

Analysts have given RCEL a Buy based on their latest research and market trends.

According to 3 analysts, RCEL has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AVITA Medical Inc (RCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.